ReviewExpert review of molecular diagnostics2016
Challenges of development and implementation of point of care pharmacogenetic testing.
Review in Expert review of molecular diagnostics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Accuracy and technical characteristics of CYP2C19 point of care tests: a systematic review.Pharmacogenomics · 2024Pooled it
- Health Economic Evidence of Point-of-Care Testing: A Systematic Review.PharmacoEconomics - open · 2021Pooled it
- Review and Consensus on Pharmacogenomic Testing in Psychiatry.Pharmacopsychiatry · 2021Pooled it
- Companion Diagnostics in Clinical Therapy: Current Applications and Future Directions.MedComm · 2026Review
- Development of a New Portable Genetic Analyzer for Point-of-Care Molecular Genetics and Pharmacogenomics Analysis.Human mutation · 2026Article
- Solanidine-derived CYP2D6 phenotyping elucidates phenoconversion in multimedicated geriatric patients.British journal of clinical pharmacology · 2025Observational
- Solanidine-derived CYP2D6 phenotyping elucidates phenoconversion in multimedicated geriatric patients.British journal of clinical pharmacology · 2025Observational
- Development of an Ancestrally Inclusive Preemptive Pharmacogenetic Testing Panel.Clinical and translational science · 2025Article
- Comparison of two polymerase chain reaction assays, DaAn Gene (DaAn Gene 2019-ncov) and Cepheid (Cepheid Xpert Xpress SARS-CoV-2) for Delta and Omicron variants of SARS-CoV-2 detection in Yaoundé, Cameroon.Journal of public health in Africa · 2025Article
- Pharmacogenomics implementation across multiple clinic settings: a qualitative evaluation.Pharmacogenomics · 2023Article
- Analyzing SDG interlinkages: identifying trade-offs and synergies for a responsible innovation.Sustainability science · 2023Article
- Advances in point-of-care genetic testing for personalized medicine applications.Biomicrofluidics · 2023Review
- Genotyping of Patients with Adverse Drug Reaction or Therapy Failure: Database Analysis of a Pharmacogenetics Case Series Study.Pharmacogenomics and personalized medicine · 2023Article
- Three Grand Challenges in High Throughput Omics Technologies.Biomolecules · 2022Article
- Portable real-time colorimetric LAMP-device for rapid quantitative detection of nucleic acids in crude samples.Scientific reports · 2022Article
- Impact of Previous Genetic Counseling and Objective Numeracy on Accurate Interpretation of a Pharmacogenetics Test Report.Public health genomics · 2021Article
- Genetic Variation ofFrontiers in pharmacology · 2021Article
- Physicians' Knowledge and Attitudes Regarding Point-of-Care Pharmacogenetic Testing: A Hospital-Based Cross-Sectional Study.Pharmacogenomics and personalized medicine · 2021Article
- Arylamine N-acetyltransferase acetylation polymorphisms: paradigm for pharmacogenomic-guided therapy- a focused review.Expert opinion on drug metabolism & toxicology · 2021Review
- Pharmacogenetic Testing Options Relevant to Psychiatry in Canada: Options de tests pharmacogénétiques pertinents en psychiatrie au Canada.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
introductionJust as technology was the underlying driver of the sequencing of the human genome and subsequent generation of volumes of genome sequence data from healthy and affected individuals, animal, plant, and microbial species alike, so too will technology revolutionize diagnostic testing. One area of intense interest is the use of genetic data to inform decisions regarding drug selection and drug dosing, known as pharmacogenetic (PGx) testing, to improve likelihood of successful treatment outcomes with minimal risks. AREAS COVERED: This commentary will provide an overview of implementation research of PGx testing, the benefits of point-of-care (POC) testing and overview of POC testing platforms, available PGx tests, and barriers and facilitators to the development and integration of POC-PGx testing into clinical settings. Sources include the published literature, and databases from the Centers for Medicaid and Medicare Services, Food and Drug Administration. Expert commentary: The utilization of POC PGx testing may enable more routine test use, but the development and implementation of such tests will face some barriers before personalized medicine is available to every patient. In particular, provider training, availability of clinical decision supports, and connectivity will be key areas to facilitate routine use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.